BioSpace News Archive

Kerstin Papenfuss, director of Therapeutics at Deep Science Ventures, is a proven leader in therapeutic venture creation, translating groundbreaking scientific ideas into successful companies. With a PhD in tumor immunology and an Executive MBA, her career spans impactful roles at LifeArc and the UK’s Cell and Gene Therapy Catapult.

An advisory committee last year found that Zynquista’s benefit-risk profile in type 1 diabetes was unfavorable due to cases of diabetic ketoacidosis.

In its rejection letter, the FDA flagged problems at a third-party fill-finish site owned by Novo Nordisk. Issues at this site have previously been investigated by the regulator.

The agency also pointed to the use of Tylenol and other acetaminophen products during pregnancy as being potentially linked to neurological and developmental defects in children, following a press conference Monday in which President Donald Trump did the same.

While last week’s recommended changes by CDC advisors to the MMRV vaccine schedule are unlikely to have a tangible effect on Merck’s business, the company said the removal of choice for healthcare providers is “concerning.”

By improving gait stability, Ionis’ zilganersen could be “potentially disease modifying,” according to analysts at William Blair.

Small and large drugmakers alike have made big, proactive moves to secure the production capacity that will be vital to serving the weight loss market.